CClinicalTrials.gg
CompletedNCT00408265Updated Nov 21, 2011

Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study

A Phase 3 interventional study of Contingency Management in Nicotine Dependence, sponsored by UConn Health. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-21.

Sponsored by UConn Health · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The purpose of this study is to compare the effects of self-help materials for smoking cessation and self-help materials for smoking cessation plus prize-based contingency management (CM), in which prize incentives are available for breath and saliva samples that indicate smoking abstinence, in substance abuse treatment patients who want to quit smoking.

Read the detailed description

The specific aims of this study are: (1) to examine the efficacy of self-help materials compared to self-help materials plus prize contingency management (CM) for smoking abstinence in substance abuse treatment patients and (2) examine the effects of smoking abstinence on substance use and substance treatment retention. To address these specific aims, cigarette smokers entering treatment for alcohol, cocaine or heroin abuse or dependence, who report daily smoking (at least one cigarette per day) for the past year, and who meet other inclusion and exclusion criteria, are randomly assigned to receive self-help materials or self-help materials plus CM. Individuals in the CM group have the opportunity to win prizes, worth on average $1, $20, or $100, when they meet smoking abstinence criteria (CO \< 8ppm and salivary cotinine \< 10ng/mL). Participants meet with research staff 4 times/week during Weeks 1-4, 2 times/week during Weeks 5-8 and 1 time/week during Weeks 9-12. Follow-up interviews are scheduled 1, 3 and 6 months following the smoking quit date.

02

Conditions studied

  • Nicotine Dependence

Keywords

  • Nicotine Dependence
  • Contingency Management
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's enrollment of 80 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

UConn Health is the lead sponsor of 182 studies on the registry; 18 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • meets diagnostic criteria for alcohol, cocaine or heroin abuse or dependence
  • self-report daily smoking for at least the past year
  • CO > 8ppm
  • interested in quitting smoking while in treatment,
  • minimum age 18 years old
  • willing to provide names, addresses and phone numbers of individuals to assist in locating the patient for follow-up evaluations
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • current use of NRT
  • current use of bupropion
  • serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, suicide risk)
  • dementia (Mini-mental status score of \<23)
  • currently participating in another CM study at the clinic
  • in recovery for pathological gambling
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Interventions

  • BehavioralContingency Management
06

What researchers measure

Primary outcomes

  1. Percent negative CO readings

  2. Percent negative cotinine readings

  3. Longest period of continuous abstinence

Secondary outcomes

  1. Self-reported frequency and severity of smoking

  2. Objective substance use

  3. Self-reported substance use

  4. Treatment retention

07

Study locations

1 site
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00408265
Lead sponsor
UConn Health
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Responsible party
Sponsor
First posted
Dec 6, 2006
Start date
Jan 2004
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Nov 21, 2011

Study contacts

Sheila M Alessi, PhD
principal investigator · UConn Health

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion